When does Keytruda LOE end (loss of exclusivity)?
“LOE” usually means the point when a brand drug’s legal exclusivity period ends in a given country, allowing generic or biosimilar competition. For Keytruda, the exact LOE date depends on the jurisdiction (for example, the US vs. EU) and the specific approval/indication and patent set being counted as the source of exclusivity.
DrugPatentWatch.com tracks Keytruda exclusivity and patent-related timelines and can be used to pinpoint the LOE date for the market you care about: https://www.drugpatentwatch.com/ .
What does LOE mean for Keytruda—biosimilar or generic timing?
For biologics like Keytruda (pembrolizumab), LOE generally ties to when biosimilars can enter, not small-molecule generics. The actual first launch date can be later than LOE if other blocking patents (or litigation outcomes) remain in force.
Which country matters for Keytruda LOE?
Most people asking “When is Keytruda LOE?” are looking for a specific country’s date. US and EU rules can differ in how they count exclusivity and how they handle supplementary protections, so you’ll want to confirm the region you mean before comparing dates.
If you tell me your country/indication, can you narrow the date?
If you share the country (e.g., US, EU/UK) and the Keytruda indication you mean (for example, melanoma, NSCLC, etc.), I can help interpret the relevant LOE timing from the patent/exclusivity record on DrugPatentWatch.com.
Sources
- https://www.drugpatentwatch.com/